KVPR

Trump administration's embattled FDA vaccine chief is leaving for the second time

The FDA's controversial vaccine chief, Dr. Vinay Prasad, is leaving the agency. It's the second time he has abruptly departed following decisions involving the review of vaccinations and specialty drugs.

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S. Food and Drug Administration.

FDA’s Controversial Vaccines Chief Will Leave the Agency

Dr. Vinay Prasad will depart in April, after a year leading the division that approves vaccines and biotech drugs.

Salmon recall update as FDA sets risk level

Exposure to this product could cause miscarriages and stillbirths as well as serious infections.
MedPage Today on MSN

RFK Jr. Says FDA Will Lift Ban on Peptides

Physicians remain wary of the wellness trend

FDA goes on offense amid surge of criticism for recent drug decisions

In a highly unusual move for a normally buttoned-up regulatory agency, a senior official with the US Food and Drug Administration held a call with reporters Thursday to defend the agency’s recent decision on an experimental medicine,

FDA official calls UniQure's Huntington's disease treatment a failure

By Michael Erman and Puyaan Singh March 5 (Reuters) - A senior FDA official called UniQure's experimental treatment for Huntington's disease a "failed product" in a conference call with media on Thursday,
Fierce Biotech

FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap

The FDA will end a roughly nine-month hiatus of drug-related advisory committee meetings, with plans to convene its first session of 2026 to scrutinize a pair of oncology applications from AstraZen | The FDA is ending a roughly nine-month hiatus of drug-related advisory committee meetings,